A Gómez-Ibáñez1, J M Serratosa2, E Guillamón3, M Garcés3, B G Giráldez2, M Toledo4, J Salas-Puig4, F J López-González5, J Rodríguez-Uranga6, A Castillo7, J A Mauri8, J L Camacho8, E López-Gomáriz9, P Giner10, N Torres10, J Palau11, A Molins12, V Villanueva3. 1. Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: asiergomez81@gmail.com. 2. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. 3. Hospital Universitario y Politécnico La Fe, Valencia, Spain. 4. Hospital Universitario Vall d'Hebron, Barcelona, Spain. 5. Complejo Hospitalario Universitario Santiago, Santiago de Compostela, Spain. 6. Instituto de Especialidades Neurológicas (IENSA), Clínica Sagrado Corazón, Sevilla, Spain. 7. Consorcio Hospital General Universitario Valencia, Valencia, Spain. 8. Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. 9. Hospital Lluis Alcanyis, Xátiva, Spain. 10. Hospital Universitario Dr. Peset, Valencia, Spain. 11. Hospital de Manises, Manises, Spain. 12. Hospital Universitario Dr. Josep Trueta, Girona, Spain.
Abstract
PURPOSE: Eslicarbazepine-acetate (ESL) is a third generation antiepileptic drug licensed as adjunctive therapy in adults with focal seizures. Efficacy and safety of ESL have been established in real-life setting. However, data about outcomes in elderly patients are scarce. Primary endpoint was to evaluate outcomes of ESL in elderly patients. METHOD: This was a retrospective survey that included patients >65years with focal seizures who started ESL between January 2010 and July 2012 at 12 Spanish Hospitals. ESL was prescribed individually according to real-life practice. Efficacy and safety were evaluated over 1year. These patients were included within the bigger study ESLIBASE. RESULTS: We included 29 patients, most of them males (18). Mean age was 71.2 year-old and epilepsy evolution was 20 years. Eighteen were pharmacorresistant at baseline. At 12 months, the mean dose was 850mg/day, the retention rate 69%, the responder rate 62% and 24.1% were seizure-free. At 12 months, 16 patients (55.2%) had ≥1 adverse effect (AE), that led to discontinuation in 7 patients. Dizziness, nausea and ataxia were the most common AEs. The tolerability profile improved in 4/5 patients who switched from carbamazepine (CBZ) or oxcarbazepine (OXC) to ESL due to AEs. CONCLUSIONS: ESL was well-tolerated and effective in elderly patients in a real-life setting over 1year, with a dose around 800mg/day. AE effects improved in most of who switched from CBZ or OXC to ESL.
PURPOSE:Eslicarbazepine-acetate (ESL) is a third generation antiepileptic drug licensed as adjunctive therapy in adults with focal seizures. Efficacy and safety of ESL have been established in real-life setting. However, data about outcomes in elderly patients are scarce. Primary endpoint was to evaluate outcomes of ESL in elderly patients. METHOD: This was a retrospective survey that included patients >65years with focal seizures who started ESL between January 2010 and July 2012 at 12 Spanish Hospitals. ESL was prescribed individually according to real-life practice. Efficacy and safety were evaluated over 1year. These patients were included within the bigger study ESLIBASE. RESULTS: We included 29 patients, most of them males (18). Mean age was 71.2 year-old and epilepsy evolution was 20 years. Eighteen were pharmacorresistant at baseline. At 12 months, the mean dose was 850mg/day, the retention rate 69%, the responder rate 62% and 24.1% were seizure-free. At 12 months, 16 patients (55.2%) had ≥1 adverse effect (AE), that led to discontinuation in 7 patients. Dizziness, nausea and ataxia were the most common AEs. The tolerability profile improved in 4/5 patients who switched from carbamazepine (CBZ) or oxcarbazepine (OXC) to ESL due to AEs. CONCLUSIONS:ESL was well-tolerated and effective in elderly patients in a real-life setting over 1year, with a dose around 800mg/day. AE effects improved in most of who switched from CBZ or OXC to ESL.